期刊文献+

恶性胸腹腔积液中肿瘤细胞的TS mRNA表达水平与培美曲塞药物敏感性关系

Relationship between mRNA expression of thymidylate synthase( TS ) in malignant pleural and peritoneal effusions and chemosensitivity to pemetrexed
原文传递
导出
摘要 目的分析恶性胸腹腔积液中原代肿瘤细胞胸苷酸合成酶(TS)基因的mRNA表达水平,探讨TS基因在恶性胸腹腔积液患者中对培美曲塞药物化疗疗效的预测作用。方法收集39例经病理确诊的Ⅳ期恶性肿瘤患者的恶性胸腹腔积液,分离原代肿瘤细胞,采用ATP-TCA法体外药物敏感试验检测化疗药物对原代肿瘤细胞的抗肿瘤作用;提取原代肿瘤细胞的总RNA,采用实时荧光定量PCR方法检测原代肿瘤细胞中培美曲塞药物疗效相关基因TS的相对表达水平。结果在恶性胸腹腔积液中,原代肿瘤细胞中TS mRNA的相对表达水平与恶性肿瘤患者的临床特征无明显相关性(P>0.05);TS mRNA表达水平与培美曲塞药敏结果呈负相关,TS低表达,培美曲塞更敏感(P<0.05)。结论恶性胸腹腔积液中原代肿瘤细胞TS mRNA的表达水平与培美曲塞体外药物敏感性相关。对于有恶性胸腹腔积液患者,可通过简单的胸腹腔穿刺获得与化疗药物疗效相关的基因信息,从而为恶性胸腹腔积液患者实施个体化治疗提供理论基础。 Objective To explore the mRNA expression of thymidylate synthase( TS) in tumor cells isolated from malignant pleural and peritoneal effusions,and to investigate the predictive role of TS to the efficacy of pemetrexed-based chemotherapy. Methods Tumor cells were isolated from malignant pleural and peritoneal effusions of 39 patients with malignant tumor. Viable tumor cells were tested for sensitivity to pemetrexed using ATP-TCA assay. RT-PCR was used to examine the TS mRNA level in the primary cultured cancer cells. Results The expression level of TS mRNA in malignant effusions was negatively correlated with pemetrexed sensitivity. The expression of TS mRNA was not related to age,gender or tumor type. Conclusions The results indicate that the expression level of TS mRNA in malignant effusions is negatively correlated with sensitivity to pemetrexed. Chest or abdominal puncture may play an important role for"real-time"individualized chemotherapy while tumor progression.
出处 《实用老年医学》 CAS 2015年第9期741-743,共3页 Practical Geriatrics
基金 江苏省卫生厅医学科研面上项目(H201329) 江苏省六大高峰项目(2013-WSN-057)
关键词 胸苷酸合成酶 恶性胸腹腔积液 培美曲塞 thymidylate synthase malignant pleural and peritoneal effusions pemetrexed
  • 相关文献

参考文献10

  • 1Christofori G. New signals from the invasive front [ J ]. Nature, 2006, 441(7092): 444-450. 被引量:1
  • 2Custodio AB, Gonz~ilez-Larriba JL, Bobokova J, et al. Prognostic and predictive markers of benefit from adjuvant chemotherapy in early-stage non-small cell lung cancer[J] .J Thorae Oncol, 2009,4(7) : 891-910. 被引量:1
  • 3樊卫飞,王峻,刘福银,杨民,孟丽娟,蒲骁麟.培美曲塞单药二线治疗26例老年晚期非小细胞肺癌临床观察[J].实用老年医学,2009,23(6):451-452. 被引量:15
  • 4Lee SH, Noh KB, Lee JS, et al. Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenoearcinoma treated with pemetrexed and cisplatin [ J ]. Lung Cancer, 2013,81 ( 1 ) : 102-108. 被引量:1
  • 5Righi L, Papotti MG, Ceppi P,et al. Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy[ J]. J Clin Oneol,2010,28(9) : 1534-1539. 被引量:1
  • 6Rosolen DC, Kulikowski LD, Bottura G, et al. Efficacy of two fluorescence in situ hybridization (FISH) probes for diagnosing malignant pleural effusions [ J ]. Lung Cancer, 2013,80(3) : 284-288. 被引量:1
  • 7Maldonado F, Astoul P. Management of recurrent malignant pleural effusions: an ever-recurring issue? [J]. Chest, 2012,142(6) : 1696-1697. 被引量:1
  • 8Richard C, Matthews D, Duivenvoorden W, et al. Flavopiridol sensitivity of cancer ceils isolated from ascites and pleural fluids [J]. Clin Cancer Res, 2005, 11(9) :3523-3529. 被引量:1
  • 9Takezawa K, Okamoto I, Okamoto W, et al. Thymidylate synthase as a determinant of pemetrexed sensitivity in non- small cell lung cancer [ J ]. Br J Cancer, 2011, 104 (10) : 1594-1601. 被引量:1
  • 10Chen CY, Chang YL, Shih JY, et al. Thymidylate synthase and Dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed [ J ] .Lung Cancer ,2011,74( 1 ) : 132-138. 被引量:1

二级参考文献12

  • 1郝学志,张湘茹,胡兴胜,王彬,赵龙妹,黄镜.培美曲塞治疗19例复发性晚期非小细胞肺癌[J].中国癌症杂志,2007,17(7):575-577. 被引量:35
  • 2Gridelli C, Perrone F, Monfardini S. Lung cancer in the elderly[J]. Eur J Cancer, 1997,33 ( 33 ) : 2313-2314. 被引量:1
  • 3孙燕译.成人及儿童肿瘤内科分册[M].北京:学术期刊出版社,1988:29. 被引量:2
  • 4Clarke SJ, Abratt R, Goedhals L, et al. Phase II trial of pemetrexed disodium in chemotherapy--naive patients with advanced non-small-cell lung cancer[J]. Ann Oncol, 2002, 13 (5) :737-741. 被引量:1
  • 5Rusthoven JJ,Eisenhauer E, Butts C, et al. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study[ J]. J Clin Oncol, 1999,17 (4) : 1194-1199. 被引量:1
  • 6Smit EF, Mattson K, yon Pawel J, et al. ALIMTA (pemetrexed disodium ) as second-line treatment of non-small-cell lung cancer: a phase II study [ J]. Ann Oncol, 2003, 14 ( 3 ) :455460. 被引量:1
  • 7Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy [ J ]. J Clin Onco1,2004,22 ( 9 ) : 1589-1597. 被引量:1
  • 8Curran MP,Plosker GL. Vinorelbine: a review of its use in elderly patients with advanced non-small-cell lung cancer [ J ]. Drugs Aging,2002,19 (9) :695-721. 被引量:1
  • 9Weiss GJ, Langer C, Rosell R, et al. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer [ J ]. J Clin Oncol, 2006, 24 (27) :4405-4411. 被引量:1
  • 10Scagliotti GV, Parikh P, Von Pawel J, et al. Phase III study comparing cisplatin plus gemciyabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced- stage non-small-cell Lung cancer[ J]. J Clin Oncol,2008,26 (21) :3543-3551. 被引量:1

共引文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部